BLDR vs STRL

The company exhibits strong financial health with a Piotroski F-Score of 7/9, indicating solid operational and balance sheet fundamentals. However, despite this strength, the business is facing significant near-term headwinds, evidenced by sharp year-over-year declines in revenue (-6.9%) and earnings (-54.9%), which are weighing on performance. Valuation metrics suggest the stock is trading at a premium to both Graham’s defensive value ($67.26) and growth-based intrinsic value ($36.05), though below the sector’s elevated average P/E. Analysts maintain a 'buy' recommendation with a $131.00 target, implying upside potential if macro or operational conditions improve.

STRL exhibits a stable financial foundation with a Piotroski F-Score of 6/9 and a very healthy Debt/Equity ratio of 0.32. However, there is a massive divergence between the current market price ($463.65) and deterministic value markers, with a Graham Number of $87.27 and an Intrinsic Value of $65.59. While revenue growth is explosive at 51.5% and the company has a stellar track record of earnings beats, the valuation is stretched (P/B of 12.83) and insider sentiment is heavily bearish. The stock is currently a high-growth momentum play trading at a significant premium to its fundamental value.